Idenix valopicitabine to start Phase III in ’06
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Idenix hopes to finalize a Phase III trial protocol for its hepatitis C agent valopicitabine by March 2006, the firm says Dec. 2. FDA requested additional data from a Phase IIb trial during a Nov. 30 end-of-Phase II meeting; Idenix plans to submit the data in January. "Valopicitabine is an orally bioavailable pro-drug of a novel ribonucleoside analog, and is an inhibitor of HCV and related viruses," Idenix says. The company has other antivirals in development, including valtorcitabine and telbivudine, both for hepatitis B. A telbivudine NDA is slated for submission before year-end...
You may also be interested in...
Novartis/Idenix HCV Studies Altered For GI Safety; Five Gleevec sNDAs Pending
Idenix’ revision to the dosing scheme across its Phase IIb clinical program for valopicitabine reflects the firm’s and FDA’s concern that serious gastrointestinal side effects could represent key dose-limiting adverse events for the hepatitis C agent.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.